Skip to main content
. Author manuscript; available in PMC: 2017 Oct 15.
Published in final edited form as: J Immunol. 2016 Sep 12;197(8):2992–3007. doi: 10.4049/jimmunol.1500411

Figure 6. The “IFN-β + MOG in Alum” vaccine elicited FOXP3+ Tregs in vivo.

Figure 6

On days 0, 7, and 26, 2D2-FIG mice were injected subcutaneously (5 nmole dose) with “IFN-β + MOG in Alum”. Another group was injected with 5 nmoles of “IFN-β + MOG in saline” on days 0 and 7 followed by one injection of “IFN-β + MOG in Alum” on day 26 (n = 2). On days 7, 14, 29, 33, and 40, mice were bled via the submandibular vein, and circulating CD45+ CD3+ T cells were assessed for expression of the 2D2 TCR transgenic Vα3.2 receptor and GFP (FOXP3+) expression. (B) The total combined percentages of transgenic Vα3.2+ and nontransgenic Vα3.2 FOXP3+ Tregs is given in the upper right of each dotplot. Analysis panels included CD25-BV421, TCR-Vα3.2-PE, CD3-PE.CF594, TCR-Vβ11-AF647, and CD45-BV785.